Bayer Aktiengesellschaft

Ilka Mathar

Frank Wunder

Markus Follmann

Thomas Mondritzki

Peter Sandner

Lucas Hudson Hofmeister

Alexandros Vakalopoulos

Carsten Schmeck

Peter Kolkhof

Simone Greven

Tobias Marquardt

Jan Tebbe

Christoph Mahlert

Lisa Dietz

Ernst Weber

Timo Stellfeld

Damian Brockschnieder

Alexey Gromov

Andreas Wilmen

Robert Alan Webster

Andre Philippe Dieskau

Stefanie Breitenstein

Lisa Candish

Melissa Boultadakis-arapinis

Nuria Ortega Hernandez

Marie-Pierre Collin-kröpelin

Anke Mayer-bartschmid

Stuart Walsh

Marcel Geertz

Claudia Noack

Hannah Jörissen

Andre Dieskau

Hahn Michael G

Michael G Hahn

Jan Dreher

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Atrial natriuretic peptide engrafted antibodies

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Substituted pyrazolo piperidine carboxylic acids

The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).

Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases

Growing community of inventors

Düsseldorf, Germany

Ilka Mathar